bluebird bio (BLUE) News Today $3.97 +0.02 (+0.51%) Closing price 05/5/2025 04:00 PM EasternExtended Trading$3.82 -0.15 (-3.65%) As of 07:21 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period New gene therapy considered cure for Sickle Cell Disease being administered at St. Louis Children’s HospitalMay 6 at 12:41 AM | msn.comCarlyle and SK Capital Receive All Required Regulatory Approvals to Complete the Acquisition of bluebird bioMay 5 at 7:39 PM | finance.yahoo.combluebird bio Inc.April 24, 2025 | wsj.comBluebird Bio Says Ayrmid Failed To Submit Formal Offer, Confirms Carlyle, SK Deal; Stock FellApril 18, 2025 | nasdaq.comBluebird bio reaffirms Carlyle deal as Ayrmid misses deadlineApril 17, 2025 | finance.yahoo.comBluebird bio shares fall amid acquisition woesApril 16, 2025 | au.investing.comBluebird reports Ayrmid did not submit binding proposal to acquire the companyApril 16, 2025 | markets.businessinsider.combluebird bio confirms that Ayrmid, Ltd. has not delivered a binding offer or obtained necessary financing despite extensive engagementApril 16, 2025 | finance.yahoo.combluebird bio's board opts for sale to U.S. investment firmsApril 16, 2025 | bizjournals.combluebird bio (NASDAQ:BLUE) Now Covered by Analysts at StockNews.comStockNews.com assumed coverage on shares of bluebird bio in a research report on Sunday. They set a "sell" rating on the stock.April 14, 2025 | marketbeat.comCharles Schwab Investment Management Inc. Has $231,000 Stock Holdings in bluebird bio, Inc. (NASDAQ:BLUE)Charles Schwab Investment Management Inc. decreased its stake in bluebird bio, Inc. (NASDAQ:BLUE - Free Report) by 95.0% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 27,652 shares of the biApril 3, 2025 | marketbeat.comBluebird Bio Receives $4.50 Per Share Acquisition Proposal From AyrmidApril 3, 2025 | nasdaq.comXcellbio Announces Commercial Licensing & Supply Agreement to Support Commercial Production of Gene Therapy for Sickle Cell diseaseApril 2, 2025 | finance.yahoo.comBluebird Bio price target lowered to $8 from $40 at BarclaysApril 1, 2025 | markets.businessinsider.comBluebird Bio (BLUE) Gets a Buy from BarclaysMarch 31, 2025 | markets.businessinsider.comBluebird Bio Shares Rise After Non-Binding Offer From AyrmidMarch 31, 2025 | marketwatch.comGene Therapy-Focused Bluebird Bio Receives Rival Takeover Offer, Stock JumpsMarch 31, 2025 | benzinga.comBluebird Bio confirms receipt non-binding proposal from AyrmidMarch 29, 2025 | markets.businessinsider.comBluebird bio reports another acquisition offer for $45M upfrontMarch 28, 2025 | bizjournals.comBluebird Bio Reviewing Buyout Offer From Ayrmid for Up to $110.5 Million -- UpdateMarch 28, 2025 | marketwatch.comBluebird bio receives non-binding bid for up to $110.5 millionMarch 28, 2025 | reuters.combluebird bio Confirms Receipt of an Unsolicited Non-Binding Proposal from AyrmidMarch 28, 2025 | businesswire.comGene therapy loses luster as investors eye quicker returns from weight-loss drugsMarch 21, 2025 | msn.comIn the Thymus We Trust: ProTcell Therapy & the Future of Allogeneic ImmunotherapyMarch 18, 2025 | msn.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of bluebird bio, inc. - BLUEMarch 17, 2025 | prnewswire.comMan Cured Of Sickle Cell Disease In New York Thanks To New Gene TherapyMarch 15, 2025 | forbes.comBristol Myers Squibb Buys Out Cancer Cell Therapy Partner 2seventy Bio In $286M DealMarch 12, 2025 | msn.comBristol-Myers Squibb To Acquire 2seventy bio - A Sad But Inevitable End To A Cell Therapy PioneerMarch 12, 2025 | seekingalpha.comBristol Myers acquires cell therapy partner 2seventy bio for about $286 millionMarch 11, 2025 | msn.com2seventy bio, Bluebird’s cell therapy spinout, sells to Bristol Myers for less than $300MMarch 11, 2025 | finance.yahoo.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of bluebird bio, inc. - BLUEMarch 11, 2025 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of bluebird bio, inc. - BLUEMarch 3, 2025 | prnewswire.comBluebird Bio upgraded to Neutral from Underweight at JPMorganFebruary 24, 2025 | markets.businessinsider.comBluebird Bio price target lowered to $5 from $40 at Wells FargoFebruary 24, 2025 | markets.businessinsider.comBluebird bio stock slides for second day on buyout newsFebruary 24, 2025 | msn.comBLUEBIRD BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of bluebird bio, Inc. - BLUEFebruary 24, 2025 | businesswire.comOnce a darling of biotech, bluebird sells for less than $30M upfrontFebruary 23, 2025 | bizjournals.comBluebird Bio to Be Acquired by Carlyle Group, SK CapitalFebruary 21, 2025 | msn.comBluebird Bio trading halted, volatility trading pauseFebruary 21, 2025 | markets.businessinsider.comALERT: Rowley Law PLLC is Investigating Proposed Acquisition of bluebird bio, Inc.February 21, 2025 | prnewswire.comOnce high-flying Bluebird Bio sells itself to private equity after tough times for the gene therapy makerFebruary 21, 2025 | cnbc.com$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of bluebird bio, Inc. - BLUEFebruary 21, 2025 | prnewswire.comShareholder Alert: Ademi LLP investigates whether bluebird bio, Inc. is obtaining a Fair Price for its Public ShareholdersFebruary 21, 2025 | businesswire.comBLUE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of bluebird bio, Inc. Is Fair to ShareholdersFebruary 21, 2025 | businesswire.combluebird bio Announces Definitive Agreement to be Acquired by Carlyle and SK CapitalFebruary 21, 2025 | businesswire.comHigh-cost sickle cell gene therapies push insurers and Medicaid programs to find new payment modelsFebruary 18, 2025 | cnbc.combluebird bio (NASDAQ:BLUE) Stock Price Passes Below Two Hundred Day Moving Average - Should You Sell?bluebird bio (NASDAQ:BLUE) Stock Passes Below 200-Day Moving Average - Here's What HappenedFebruary 14, 2025 | marketbeat.combluebird bio, Inc. (NASDAQ:BLUE) Given Consensus Rating of "Hold" by BrokeragesShares of bluebird bio, Inc. (NASDAQ:BLUE - Get Free Report) have been assigned an average rating of "Hold" from the nine analysts that are presently covering the firm, Marketbeat reports. Two research analysts have rated the stock with a sell rating, five have issued a hold rating and two have giFebruary 6, 2025 | marketbeat.comBluebird bio chief business officer Joseph Vittiglio sells $1,759 in stockFebruary 5, 2025 | msn.comBluebird bio's chief commercial officer Klima sells $901 in stockFebruary 5, 2025 | msn.com Get bluebird bio News Delivered to You Automatically Sign up to receive the latest news and ratings for BLUE and its competitors with MarketBeat's FREE daily newsletter. Email Address BLUE Media Mentions By Week BLUE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BLUE News Sentiment▼0.000.72▲Average Medical News Sentiment BLUE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BLUE Articles This Week▼13▲BLUE Articles Average Week Get bluebird bio News Delivered to You Automatically Sign up to receive the latest news and ratings for BLUE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Korro Bio News Today Inhibikase Therapeutics News Today ProQR Therapeutics News Today Tango Therapeutics News Today 4D Molecular Therapeutics News Today Tiziana Life Sciences News Today LifeVantage News Today Larimar Therapeutics News Today Nanobiotix News Today Puma Biotechnology News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BLUE) was last updated on 5/6/2025 by MarketBeat.com Staff From Our PartnersTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredMost traders are panicking. We’re cashing inMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAIEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...Brownstone Research | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | SponsoredTrump announcement boosts “next Bitcoin”President Trump just made his first big crypto move ... Announcing the creation of a national strategic re...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding bluebird bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share bluebird bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
